Dr. Amit Vijapura MD
Owner, AMIT VIJAPURA MD
Member of the Healthcare Council
Council Member Biography
Amit Vijapura, MD, is a Private Practitioner in Psychiatry based in Florida. Dr. Vijapura is the President of Psychiatric Institute of Clinical Research. He has over 21 years of experience in the field and has expertise in depression, bipolar disorder, anxiety disorder, attention deficient disorder, and schizophrenia. Dr. Vijapura is board certified in Psychiatry and is also involved in teaching at the local, regional, and national level for different disease and pharmaceutical products. He is also running a clinical research site with three research coordinators and has been taking part in many Phase II and Phase III trials. Dr. Vijapura is familiar with research data for many new compounds for major depression such as Amibegeron, Desvenlafaxine, and Saredutant. (This is me - Update Profile)
Employment History
- 1991 - Unspecified
- President, Psychiatric Institute of Clinical Research
- 1991 - Unspecified
- Owner, AMIT VIJAPURA MD
GLG NewsSM Analyses by Amit Vijapura
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Lilly has great product pipe line for Schizophrenia and other Psychiatric Disorders
September 24, 2007
Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds | www.pipelinereview.com
Lilly is currently leader in Psychiatry with 4 active medications with great marketing for Psychiatry and Primary care physician. New compound that has a unique mechanism on Metabotropic Glutamate 2/3 Receptors, can work on Schizophrenia and other Psychiatric diagnosis. This is great opportunity for Lilly to continue with its leaders ship position in Psychiatry market, which is a fasted growing sector in medical research. LY2140023 is still going thru Phase II trials and its results are not yet released.
-
Quetiapine and Borderline personality disorder
September 1, 2006
Quetiapine Effective for Borderline Personality Disorder | www.medscape.com
How is Borderline personality disorder treated in Psychiatry practice ?
Use of Quetiapine (Seroquel) in B.P.D. -
ADHD treatment with Stimulant drugs and current FDA warning
August 24, 2006
UPDATE 2-US FDA calls for new warnings on ADHD drugs | yahoo.reuters.com
Treatment of ADHD is fastest growing market in USA and abroad. New warning by FDA can affect prescription growth and can have major impact on companies like SHIRE who is heavily relying on Stimulant medication use for their profit.
GLG Study Groups with Amit Vijapura(?)
| Study Group Name | No. Members |
|---|---|
| Psychiatrists | 1655 |
| Psychiatrists (US) | 1207 |
| Generic Drug Economic Experts | 890 |
| Physicians who Treat Depression (US) | 535 |
| Physicians who Treat ADHD (US) | 533 |
GLG Live Meetings with Amit Vijapura(?)
Amit Vijapura has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.